Agree mostly with your analysis.Unfortunately ASIC are...

Agree mostly with your analysis.

Unfortunately ASIC are untroubled by all sorts of things that are wrong with the market and specific company dealings.

For six months the stock was held down and accumulated by the very entities that sold out to Cephalon. It was clearly and inside job and very carefully orchestrated.

The premium Peptech got for Domantis was massive compared to the dribble the Cephalon are offering.

The whole thing is too convenient and happening too fast to be in the best interests of shareholders and the Australian biotech industry.

I, like many others have been waiting for the results of the trial and those sneaky directors release the results after the takeover offer effectively shutting out a whole raft of potential investors.

I am interested in what the current buyers thoughts are - as there are some very large orders going through. Is it a dividend and arbitrage play or anticipation of a substantially higher offer?